Floatz logo

PBR-06

MSA - Multiple System Atrophy

Brigham and Women's HospitalSmall moleculeEarly Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

26 Active assets in the MSA - Multiple System Atrophy cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
IOFLUPANE
GE Healthcare
Phase 3B
ATH-434
Alterity Therapeutics
Phase 2B
Riluzole
King's College London
Phase 3B

View all 40 →

Same molecule, other indications

PBR-06 is also rated in:

relapsing-remitting multiple sclerosisDormant
CCC
Indicative ·
55 / 100
View asset →
stroke disorderDormant
CC
Indicative ·
47 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →